Concurrent Technologies Experiences Strong Growth in First-Half Revenues and Profits

1 Mins read

London-based computer systems and boards manufacturer, Concurrent Technologies, has reported a significant increase in first-half revenue and pretax profit, surpassing market expectations. As a result, the company’s share prices saw a surge of 11% to 63.50 pence at 0707 GMT.

During the first half of the year, Concurrent Technologies expects to report revenue of approximately £12 million, compared to £7.4 million in the same period in 2022. Furthermore, pretax profit is anticipated to reach £1 million, a substantial improvement from £100,000 in the previous year.

The company attributes its success to strong order intake, amounting to £14.5 million in the first half, and an order backlog of approximately £29 million as of June 30.

While supply chains have not fully returned to normal yet, there have been noticeable improvements. As components become more readily available, Concurrent Technologies anticipates a period of growth.

Looking ahead to the second half of the year, the company expects further improvement in revenue compared to its record-breaking first-half results. Consequently, it foresees full-year revenue slightly exceeding market consensus expectations of £25 million, with pretax profit significantly surpassing market views of £2.7 million.

Chief Executive Miles Adcock expressed confidence in the company’s future potential, stating, “Following a period of ongoing transformation, this business now has the capability, capacity, and ambition to deliver sustained growth.”

Related posts

Your Social Security Checks are Safe

2 Mins read
Don’t worry, the impending federal government shutdown will not put your monthly Social Security checks in jeopardy. This is certainly a relief…

European Stocks Experience Decrease

1 Mins read
The European stock market saw a decline on Friday, with the Stoxx Europe 600 index finishing down 0.31% at 453.26. Individual Index…

Positive Results for Cancer-Drug Combination in Bladder Cancer Study

1 Mins read
A recent Phase 3 study conducted by Merck & Co., Seagen, and Astellas Pharma has achieved its primary goals in certain patients…

Leave a Reply

Your email address will not be published. Required fields are marked *